Home / Healthcare / Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H1 2016

Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H1 2016

Published: Apr 2016 | No Of Pages: 47 | Published By: Global Markets Direct

Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H1 2016

<b>Summary</b>

Global Markets Direct’s, ‘Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H1 2016’, provides in depth analysis on Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted pipeline therapeutics.

The report provides comprehensive information on the Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

<b>Scope</b>

- The report provides a snapshot of the global therapeutic landscape for Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR)
- The report reviews Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics and enlists all their major and minor projects
- The report assesses Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics

<b>Reasons to buy</b>

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) Overview 7
Therapeutics Development 8
Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Products under Development by Stage of Development 8
Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Products under Development by Therapy Area 9
Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Products under Development by Indication 10
Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Products under Development by Companies 13
Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Products under Development by Universities/Institutes 15
Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 20
Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Companies Involved in Therapeutics Development 22
Alchemia Limited 22
AstraZeneca Plc 23
Carmot Therapeutics, Inc. 24
Diabetica Limited 25
Longevity Biotech, Inc 26
Novo Nordisk A/S 27
Sanofi 28
Zealand Pharma A/S 29
Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Drug Profiles 30
AC-163794 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
LBT-6030 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
NN-9709 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
SAR-438335 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecule to Agonize Gastric Inhibitory Polypeptide for Type 2 Diabetes - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecules to Agonize GLP-1 and GIP Receptors for Diabetes and Obesity - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Synthetic Peptide 1 for Type 2 Diabetes and Obesity - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Synthetic Peptide 1 to Agonize GIPR for Alzheimer's Disease - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Synthetic Peptide to Agonize GIPR for Alzheimer's Disease - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Synthetic Peptides to Agonize GLP-1, GIP and Glucagon Receptors for Diabetes and Obesity - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
ZPDI-70 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
ZPI-98 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Dormant Projects 42
Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Discontinued Products 43
Gastric Inhibitory Polypeptide Receptor (GIP-R or Glucose-Dependent Insulinotropic Polypeptide Receptor or GIPR) - Featured News & Press Releases 44
Sep 15, 2015: Zealand presents new preclinical data on its novel GIP peptide therapeutic, ZP-I-98, at the 51st EASD Annual Meeting 44
Jun 06, 2015: Presentations on ZP-DI-70, novel Zealand preclinical peptide therapeutics as a possible approach for the treatment of Type 2 diabetes and obesity at the American Diabetes Association’s (ADA) 74th Scientific Sessions 44
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47

Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Assessment by Monotherapy/Combination Products, H1 2016 17
Number of Products by Stage and Mechanism of Action, H1 2016 18
Number of Products by Stage and Route of Administration, H1 2016 19
Number of Products by Stage and Molecule Type, H1 2016 21
Pipeline by Alchemia Limited, H1 2016 22
Pipeline by AstraZeneca Plc, H1 2016 23
Pipeline by Carmot Therapeutics, Inc., H1 2016 24
Pipeline by Diabetica Limited, H1 2016 25
Pipeline by Longevity Biotech, Inc, H1 2016 26
Pipeline by Novo Nordisk A/S, H1 2016 27
Pipeline by Sanofi, H1 2016 28
Pipeline by Zealand Pharma A/S, H1 2016 29
Dormant Projects, H1 2016 42
Discontinued Products, H1 2016 43

Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Top 10 Indication, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy/Combination Products, H1 2016 17
Number of Products by Stage and Mechanism of Actions, H1 2016 18
Number of Products by Molecule Types, H1 2016 20
Number of Products by Stage and Molecule Type, H1 2016 20

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +